DE223762T1 - Zusammensetzung fuer den zellstoffwechsel. - Google Patents
Zusammensetzung fuer den zellstoffwechsel.Info
- Publication number
- DE223762T1 DE223762T1 DE198686850396T DE86850396T DE223762T1 DE 223762 T1 DE223762 T1 DE 223762T1 DE 198686850396 T DE198686850396 T DE 198686850396T DE 86850396 T DE86850396 T DE 86850396T DE 223762 T1 DE223762 T1 DE 223762T1
- Authority
- DE
- Germany
- Prior art keywords
- mmol
- composition according
- composition
- magnesium
- hpo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract 16
- 230000019522 cellular metabolic process Effects 0.000 title claims abstract 4
- 239000011777 magnesium Substances 0.000 claims abstract 5
- 229910052700 potassium Inorganic materials 0.000 claims abstract 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract 3
- 229910052749 magnesium Inorganic materials 0.000 claims abstract 3
- 239000011591 potassium Substances 0.000 claims abstract 3
- 235000019577 caloric intake Nutrition 0.000 claims abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract 2
- 239000011780 sodium chloride Substances 0.000 claims abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 235000014659 low sodium diet Nutrition 0.000 claims 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical class [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims 1
- 239000004137 magnesium phosphate Substances 0.000 claims 1
- 235000010994 magnesium phosphates Nutrition 0.000 claims 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000037213 diet Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Special Wing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Seasonings (AREA)
- Saccharide Compounds (AREA)
- Detergent Compositions (AREA)
Claims (9)
1. Zusammensetzung zur Verbesserung des Zellmetabolismus
bei Menschen mit adäquatem Kalorienverbrauch, jedoch in Kombination mit physiologischer oder salzarmer Diät, d.h.
einem korrekten Verbrauch von Natriumchlorid, dadurch
gekenn zeichnet, daß die Zusammensetzung Kalium-, Magnesium- und Phosphationeri in einer täglichen
Dosis von 30-80 mmol K , O-20 mmol Mg und 15-50 mmol
HPO
2-
1-
. und/oder H3PO4' oder andere Kalium- oder Magnesiumphosphate
in Form von physiologisch verträglichen Verbindungen enthält.
2. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet,
daß die physiologisch verträglichen Verbindungen kaliumdihydrophat und Magnesium-hydrophosphat sind.
3. Zusammensetzung nach Anspruch 1 und 2, dadurch gekenn- ■
zeichnet, daß sie Kohlehydrat enthält.
4. Zusammensetzung nach Anspruch 3> dadurch gekennzeichnet, daß sie Sacharose, Glukose und/oder Fruktose enthält.
5. Zusammensetzung nach Anspruch 3 und 4, dadurch gekennzeichnet, daß sie Kohlehydrat in einer etwa 3-8g Glukose
äquivalenten Menge enthält.
6. Zusammensetzung nach Anspruch 1 bis 5, dadurch gekennzeichnet, daß sie 40-60 mmol K+, 10 mmol Mg + und 20-40
1 oder Ho^O. oder eine Mischung davon enthält.
mmol HPO
2-
7. Zusammensetzung nach Anspruch 1 bis 5, dadurch gekenn
zeichnet, daß sie 50 mmol K , 10 mmol M
2 +
und 30-35 mmol
HPO4 2 oder H3PO4
1-
oder eine Mischung davon enthält.
8. Zusammensetzung nach Anspruch 1 bis 7, dadurch gekennzeichnet,
daß sie die Form eines Pulvers hat, welches in Flüssigkeit gelöst oder suspendiert oder mit der Nahrung
vermischt werden soll..
9. Zusammensetzung nach Anspruch 1 bis 7, dadurch gekennzeichnet, daß sie die Form von Tabletten hat, die in
Flüssigkeit aufzulösen sind, zu kauen oder ganz zu verschlucken sind, oder die Form einer Suspension oder von
Kapseln hat.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8505527A SE468074B (sv) | 1985-11-22 | 1985-11-22 | Preparat foer foerbaettring av den cellulaera metabolismen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE223762T1 true DE223762T1 (de) | 1987-10-15 |
Family
ID=20362216
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8686850396T Expired - Fee Related DE3684882D1 (de) | 1985-11-22 | 1986-11-18 | Verwendung einer zusammensetzung zur herstellung eines medikaments zur verbesserung des zellstoffwechsels. |
| DE198686850396T Pending DE223762T1 (de) | 1985-11-22 | 1986-11-18 | Zusammensetzung fuer den zellstoffwechsel. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8686850396T Expired - Fee Related DE3684882D1 (de) | 1985-11-22 | 1986-11-18 | Verwendung einer zusammensetzung zur herstellung eines medikaments zur verbesserung des zellstoffwechsels. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0223762B1 (de) |
| JP (1) | JPH07100660B2 (de) |
| AT (1) | ATE74760T1 (de) |
| AU (1) | AU592385B2 (de) |
| CA (1) | CA1275927C (de) |
| DE (2) | DE3684882D1 (de) |
| DK (1) | DK164200C (de) |
| FI (1) | FI864749A (de) |
| NO (1) | NO175845C (de) |
| SE (1) | SE468074B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU207800B (en) * | 1990-05-10 | 1993-06-28 | Andras Sikter | Process for producing composition for improving condition and for treating different illnesses |
| US5639471A (en) * | 1995-06-06 | 1997-06-17 | Campbell Soup Company | Method for determining diet program effectiveness |
| DE19925483A1 (de) * | 1998-06-04 | 2000-02-03 | Ludwig Schwebel | Wirkstoff zur Behandlung der Zuckerkrankheit |
| GB9819530D0 (en) | 1998-09-09 | 1998-10-28 | Smithkline Beecham Plc | Novel compositions and use |
| US9585827B2 (en) * | 2000-01-21 | 2017-03-07 | The Procter & Gamble Company | Kits comprising a beverage composition and information for use |
| CN102949413B (zh) * | 2012-06-08 | 2014-12-03 | 辽宁海思科制药有限公司 | 一种转化糖电解质注射液的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1796976A (en) * | 1975-09-23 | 1978-04-06 | Johnson & Johnson | Electrolyte mixtures and drinks |
| US4322407A (en) * | 1978-12-11 | 1982-03-30 | Vitapharm Pharmaceutical Pty. Ltd. | Electrolyte drink |
-
1985
- 1985-11-22 SE SE8505527A patent/SE468074B/sv not_active Application Discontinuation
-
1986
- 1986-11-14 AU AU65133/86A patent/AU592385B2/en not_active Ceased
- 1986-11-18 AT AT86850396T patent/ATE74760T1/de not_active IP Right Cessation
- 1986-11-18 DE DE8686850396T patent/DE3684882D1/de not_active Expired - Fee Related
- 1986-11-18 JP JP61273068A patent/JPH07100660B2/ja not_active Expired - Lifetime
- 1986-11-18 DE DE198686850396T patent/DE223762T1/de active Pending
- 1986-11-18 EP EP86850396A patent/EP0223762B1/de not_active Expired - Lifetime
- 1986-11-21 FI FI864749A patent/FI864749A/fi not_active Application Discontinuation
- 1986-11-21 CA CA000523514A patent/CA1275927C/en not_active Expired - Fee Related
- 1986-11-21 NO NO864682A patent/NO175845C/no unknown
- 1986-11-21 DK DK560286A patent/DK164200C/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE8505527L (sv) | 1987-05-23 |
| AU6513386A (en) | 1987-05-28 |
| FI864749A0 (fi) | 1986-11-21 |
| SE8505527D0 (sv) | 1985-11-22 |
| CA1275927C (en) | 1990-11-06 |
| NO864682L (no) | 1987-05-25 |
| DE3684882D1 (de) | 1992-05-21 |
| FI864749A (fi) | 1987-05-23 |
| DK560286A (da) | 1987-05-23 |
| NO175845B (de) | 1994-09-12 |
| SE468074B (sv) | 1992-11-02 |
| EP0223762B1 (de) | 1992-04-15 |
| EP0223762A1 (de) | 1987-05-27 |
| AU592385B2 (en) | 1990-01-11 |
| NO864682D0 (no) | 1986-11-21 |
| JPH07100660B2 (ja) | 1995-11-01 |
| NO175845C (no) | 1994-12-21 |
| ATE74760T1 (de) | 1992-05-15 |
| DK164200B (da) | 1992-05-25 |
| DK560286D0 (da) | 1986-11-21 |
| JPS62171654A (ja) | 1987-07-28 |
| DK164200C (da) | 1992-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69233250T2 (de) | Kombinationen aus calzium und vitamin d | |
| DE69528801T2 (de) | Kalziumnahrungszusatz | |
| Watson et al. | Food iron and lead absorption in humans | |
| HUT45194A (en) | Process for production of medical composition | |
| HUT47575A (en) | Process for production of piperasinal derivatives of purine and medical compositions containing them | |
| Hodges et al. | Human pantothenic acid deficiency produced by omega-methyl pantothenic acid | |
| PETERS et al. | Status epilepticus as a complication of concurrent electroconvulsive and theophylline therapy | |
| Phinney et al. | Normal cardiac rhythm during hypocaloric diets of varying carbohydrate content | |
| DE3875867T2 (de) | Kalziumzusaetze. | |
| DE223762T1 (de) | Zusammensetzung fuer den zellstoffwechsel. | |
| FI98193C (fi) | Menetelmä ravinto-, rehu ja lääkeaineiden magnesiumlisäaineen valmistamiseksi | |
| EP0304986A2 (de) | Verwendung von bestimmten Calcium-Citrate-Malaten zur Herstellung einer pharmazeutischen Zubereitung für die Behandlung von Osteoporose. | |
| DE4134723C1 (de) | ||
| EP0098975B1 (de) | Biostimulierendes Mittel | |
| Knochel et al. | Selective phosphorus deficiency in the hyperalimented hypophosphatemic dog and phosphorylation potentials in the muscle cell | |
| DE2642768C2 (de) | ||
| US4591506A (en) | Oral ingestion of indium | |
| DE2947186A1 (de) | Traubenzuckermischung und verfahren zu ihrer herstellung | |
| CA1198058A (en) | Biostimulating agent | |
| DE4212122C2 (de) | Diätetisches energiearmes Lebensmittel zur Unterstützung ärztlicher und nicht-ärztlicher Maßnahmen gegen Osteoporose | |
| Gasperetti | Conduction abnormalities complicating carbamazepine therapy | |
| GR3002449T3 (en) | Fitness drink powder | |
| Reid et al. | Flaccid quadriparesis due to Salmonella enteritis | |
| Inoue et al. | Herpes zoster ophthalmicus with contralateral hemiplegia and normal pressure hydrocephalus | |
| CA1104930A (en) | Oral ingestion of indium |